Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Christof Rottenburger
Based on 4 articles published since 2010
(Why 4 articles?)
||||

Between 2010 and 2020, Christof Rottenburger wrote the following 4 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Review Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging. 2016

Baumann, Tobias / Rottenburger, Christof / Nicolas, Guillaume / Wild, Damian. ·Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland. · Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland; Center of Neuroendocrine and Endocrine Tumors, University of Basel Hospital, Basel, Switzerland. · Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland; Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK. · Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland; Center of Neuroendocrine and Endocrine Tumors, University of Basel Hospital, Basel, Switzerland. Electronic address: damian.wild@usb.ch. ·Best Pract Res Clin Endocrinol Metab · Pubmed #26971843.

ABSTRACT: Detection of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and monitoring of treatment response relies mainly on morphological imaging such as computed tomography (CT) and magnetic resonance imaging (MRI). Molecular imaging techniques also in combination with CT (hybrid imaging) greatly benefit patient management, including better localization of occult tumours and better staging. Somatostatin receptor scintigraphy (SRS) and somatostatin receptor (SSTR) positron emission tomography (PET) play a central role in the diagnostic work-up of patients with well-differentiated GEP-NETs. SSTR PET/CT is superior to SRS and should be used whenever available. (18)F-DOPA and (18)F-FDG PET/CT is inferior to SSTR PET/CT at least in patients with well-differentiated GEP-NETs. Both SSTR PET/CT and SRS have limitations, such as relatively low detection rate of benign insulinomas, poorly differentiated GEP-NETs and liver metastases. New innovations such as SSTR PET/MRI, radiolabelled SSTR antagonists and glucagon-like peptide-1 receptor (GLP-1R) agonists might further improve imaging of GEP-NETs.

2 Clinical Trial Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. 2018

Antwi, Kwadwo / Fani, Melpomeni / Heye, Tobias / Nicolas, Guillaume / Rottenburger, Christof / Kaul, Felix / Merkle, Elmar / Zech, Christoph J / Boll, Daniel / Vogt, Deborah R / Gloor, Beat / Christ, Emanuel / Wild, Damian. ·Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, CH-4031, Basel, Switzerland. · Centre for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Petersgraben 4, Basel, Switzerland. · Clinical Trial Unit, Department of Clinical Research, University Hospital Basel and University of Basel, Spitalstrasse, 12, Basel, Switzerland. · Department of Visceral Surgery, University Hospital of Bern, Inselspital, Bern, Switzerland. · Division of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Petersgraben 4, Basel, Switzerland. · Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, CH-4031, Basel, Switzerland. damian.wild@usb.ch. · Centre for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Petersgraben 4, Basel, Switzerland. damian.wild@usb.ch. ·Eur J Nucl Med Mol Imaging · Pubmed #30054698.

ABSTRACT: PURPOSE: Benign insulinomas are the most prevalent cause of endogenous hyperinsulinaemic hypoglycaemia (EHH) in adults, and because of their small size are difficult to localise. The purpose of the study was to test the diagnostic accuracy and clinical impact of glucagon-like peptide-1 receptor (GLP-1R) PET/CT using METHODS: We prospectively enrolled patients with neuroglycopenic symptoms due to EHH. GLP-1R PET/CT, SPECT/CT and study-MRI were performed in a randomised, crossover order within 3-4 days. The reference standard was surgery with histology and treatment outcome. RESULTS: From January 2014 until March 2017, 52 patients were recruited. All imaging and invasive procedures before recruitment identified suspicious lesions in 46.2% of patients. GLP-1R PET/CT, SPECT/CT and study-MRI detected suspicious lesions in 78.8%, 63.5% and 63.4% of patients, respectively. In 38 patients, conclusive histology was available for final analysis. Accuracy (95% confidence interval) for PET/CT, SPECT/CT, study-MRI and prior external CT/MRI was 93.9% (87.8-97.5%), 67.5% (58.1-76.0%), 67.6% (58.0-76.1%) and 40.0% (23.9-57.9%), respectively (all P values < 0.01, except comparison of SPECT/CT and study-MRI with a P value = 1.0). Impact on clinical management was 42.3%, 32.7% and 33.3% for PET/CT, SPECT/CT and study-MRI, respectively. Percentage reading agreement was 89.5%, 75.7%, and 71.1% for PET/CT, SPECT/CT and study-MRI, respectively.

3 Article A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy-68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation. 2018

Rottenburger, Christof / Papantoniou, Dimitrios / Mandair, Dalvinder / Caplin, Martyn / Navalkissoor, Shaunak. · ·Clin Nucl Med · Pubmed #29432346.

ABSTRACT: Glucagonoma is an extremely rare, glucagon-secreting neuroendocrine tumor of the pancreas. Only sparse data are available about the characteristics of this tumor in somatostatin receptor imaging and only for the situation of initial diagnosis. We present a series of 3 glucagonoma patients who underwent at least 1 Ga-DOTATATE PET/CT scan. All patients were diagnosed by either histology and/or elevated serum levels of glucagon. The presented cases suggest that somatostatin receptor-based imaging can probably be used for re-evaluation of disease status in patients with glucagonoma in a similar way as it is already established for neuroendocrine tumors of other origin.

4 Article Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. 2015

Antwi, Kwadwo / Fani, Melpomeni / Nicolas, Guillaume / Rottenburger, Christof / Heye, Tobias / Reubi, Jean Claude / Gloor, Beat / Christ, Emanuel / Wild, Damian. ·Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland. · Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Bern, Bern, Switzerland. · Department of Visceral Surgery, University Hospital of Bern, Bern, Switzerland; and. · Division of Endocrinology, Diabetology, and Clinical Nutrition, University Hospital of Bern, Bern Switzerland. · Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland damian.wild@usb.ch. ·J Nucl Med · Pubmed #25999434.

ABSTRACT: METHODS: (68)Ga-DOTA-exendin-4 PET/CT and (111)In-DOTA-exendin-4 SPECT/CT were performed in a randomized cross-over order on 5 patients with endogenous hyperinsulinemic hypoglycemia. The gold standard for comparison was the histologic diagnosis after surgery. RESULTS: In 4 patients histologic diagnosis confirmed a benign insulinoma, whereas one patient refused surgery despite a positive (68)Ga-DOTA-exendin-4 PET/CT scan. In 4 of 5 patients, previously performed conventional imaging (CT or MR imaging) was not able to localize the insulinoma. (68)Ga-DOTA-exendin-4 PET/CT correctly identified the insulinoma in 4 of 4 patients, whereas (111)In-DOTA-exendin-4 SPECT/CT correctly identified the insulinoma in only 2 of 4 patients. CONCLUSION: These preliminary data suggest that the use of (68)Ga-DOTA-exendin-4 PET/CT in detecting hidden insulinomas is feasible.